NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
03/05/2026
Back to search
Official data from USPTO
VIBERZI
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
45
Latest update
03/24/2026
Trademark type
Word
Nice classes
5
Filing date
12/15/2014
Registration date
03/29/2016
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/05/2026
Last transaction
03/24/2026
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
12/14/2015
First use in commerce
12/14/2015
Drawing code
4
Owner type
99
Owner location
DUBLIN, IE
Examiner
MCBRIDE, THEODORE M
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
ALLERGAN HOLDINGS UNLIMITED COMPANY
FURIEX PHARMACEUTICALS, LLC
Furiex Pharmaceuticals, Inc.
Representatives
Maryam Arastu AbbVie Inc.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
OralTransdermalInjectable and Intravaginal Contraceptives; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the sensory organs; Pharmaceuticals and medicines for the central nervous system; Pharmaceuticals and medicines for the urogenital organs; Pharmaceuticals and medicines for the circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tractgastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome ; Pharmaceutical preparations that supportencourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; AntibioticsAntifungalsAntivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's diseasedementiaAIDS-related dementiaCNSneurological disordersneurodegenerative disordersdepressionneuroprotective agent; antidepressants; antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Excluding pharmaceuticals for the diagnosis and/or treatment of diabetes
Publications
History of USPTO decisions and trademark events.
45 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
03/05/2026
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
03/05/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/05/2026
E89R
TEAS SECTION 8 & 9 RECEIVED
12/09/2025
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
03/29/2025
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
07/19/2022
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
07/19/2022
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
07/19/2022
E815
TEAS SECTION 8 & 15 RECEIVED
02/09/2022
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
03/29/2021
A7OK
AMENDMENT UNDER SECTION 7 - PROCESSED
01/07/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/05/2021
ES7R
TEAS SECTION 7 REQUEST RECEIVED
10/06/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/06/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/06/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/06/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/06/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/06/2020
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
08/10/2016
R.PR
REGISTERED-PRINCIPAL REGISTER
03/29/2016
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
02/25/2016
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
02/24/2016
SUPC
STATEMENT OF USE PROCESSING COMPLETE
02/06/2016
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
01/28/2016
IUAF
USE AMENDMENT FILED
12/15/2015
EISU
TEAS STATEMENT OF USE RECEIVED
12/15/2015
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/15/2015
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
11/04/2015
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
08/04/2015
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/09/2015
PUBO
PUBLISHED FOR OPPOSITION
06/09/2015
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/20/2015
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
05/06/2015
ALIE
ASSIGNED TO LIE
05/06/2015
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/14/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/08/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/08/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/08/2015
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/27/2015
GNRT
NON-FINAL ACTION E-MAILED
03/27/2015
CNRT
NON-FINAL ACTION WRITTEN
03/27/2015
DOCK
ASSIGNED TO EXAMINER
03/25/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/19/2014
NWAP
NEW APPLICATION ENTERED
12/18/2014
Continuous trademark protection
Get notified about every new filing that threatens VIBERZI or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.